Leptomeningeal metastases (LM) currently lack standardization with respect to response assessment. A Response Assessment in Neuro-Oncology (RANO) working group with expertise in LM developed a consensus proposal for evaluating patients treated for this disease. Three basic elements in assessing response in LM are proposed: a standardized neurological examination, cerebral spinal fluid (CSF) cytology or flow cytometry, and radiographic evaluation. The group recommends that all patients enrolling in clinical trials undergo CSF analysis (cytology in all cancers; flow cytometry in hematologic cancers), complete contrast-enhanced neuraxis MRI, and in instances of planned intra-CSF therapy, radioisotope CSF flow studies. In conjunction with the RANO Neurological Assessment working group, a standardized instrument was created for assessing the neurological exam in patients with LM. Considering that most lesions in LM are nonmeasurable and that assessment of neuroimaging in LM is subjective, neuroimaging is graded as stable, progressive, or improved using a novel radiological LM response scorecard. Radiographic disease progression in isolation (ie, negative CSF cytology/flow cytometry and stable neurological assessment) would be defined as LM disease progression. The RANO LM working group has proposed a method of response evaluation for patients with LM that will require further testing, validation, and likely refinement with use.

Additional Metadata
Keywords CSF cytology/flow cytometry, Leptomeningeal metastasis, Neuraxis MRI, Neurological examination
Persistent URL dx.doi.org/10.1093/neuonc/now183, hdl.handle.net/1765/100008
Journal Neuro-Oncology
Citation
Chamberlain, M.C, Junck, L, Brandsma, D, Soffietti, R, Rudà, R, Raizer, J, … Jaeckle, K. (2017). Leptomeningeal metastases: A RANO proposal for response criteria. Neuro-Oncology (Vol. 19, pp. 484–492). doi:10.1093/neuonc/now183